Generalized Anxiety Disorder
A chronic condition of excessive, uncontrollable worry about everyday life events, accompanied by physical symptoms like muscle tension and fatigue.
Emergency Management: Acute panic attacks (often co-occurring) or acute suicidality requiring emergency psychiatric evaluation and possible inpatient stabilization.
Generalized Anxiety Disorder (GAD) is a chronic psychiatric condition characterized by excessive, uncontrollable, and irrational worry about everyday things (e.g., finances, health, family, minor matters) occurring more days than not for at least 6 months. It causes significant distress and impairment in social or occupational functioning.
Detailed Overview
Unlike panic disorder, which involves acute bursts of terror, GAD involves a pervasive state of 'free-floating' anxiety. Patients find it incredibly difficult to control the worry. This psychological state is coupled with somatic symptoms such as muscle tension, fatigue, and sleep disturbances. GAD is highly comorbid with Major Depressive Disorder and other anxiety disorders. It follows a chronic, fluctuating course, often worsening during periods of psychosocial stress.
Epidemiology & Demographics
Lifetime prevalence is approximately 5-6% in the United States. It is twice as common in women as in men. Onset usually occurs in early adulthood, but many patients report having been 'anxious all their life.'
Etiological Mechanism
The etiology is multifactorial, involving a combination of genetic predisposition (heritability is ~30%), neurobiological imbalances, and environmental stressors.
Primary Causes
Genetic Predisposition
Altered Brain Chemistry (Serotonin, GABA, Norepinephrine imbalances)
Environmental Stressors (Childhood trauma, chronic stress)
Neurobiologically, GAD is associated with hyperactivity of the amygdala, the brain region responsible for processing fear and threatening stimuli. There is also reduced connectivity between the amygdala and the prefrontal cortex, leading to a failure of top-down inhibitory control over the fear response. Neurotransmitter imbalances play a key role: decreased inhibitory signaling of GABA, and dysregulation of serotonin (5-HT) and norepinephrine. The autonomic nervous system is chronically in a mild state of hyperarousal.
Diagnostic Criteria & Guidelines
DSM-5 Criteria: Excessive anxiety and worry occurring more days than not for at least 6 months, about a number of events. The worry is difficult to control. Associated with 3 or more of the following 6 symptoms: restlessness, easily fatigued, difficulty concentrating, irritability, muscle tension, sleep disturbance. (Only 1 item is required for children).
Cognitive Behavioral Therapy (CBT) and/or SSRIs/SNRIs. First-line medications include Escitalopram (10-20 mg/day), Sertraline (50-200 mg/day), or Venlafaxine XR (75-225 mg/day). Note: Antidepressants should be started at half the normal dose for anxiety to prevent initial activation/worsening of symptoms.
Second-Line & Adjunctive Therapy
Buspirone (10-30 mg BID), a 5-HT1A partial agonist. Pregabalin (75-300 mg BID) where approved. Benzodiazepines (e.g., Clonazepam 0.25-0.5 mg BID) only for short-term bridge therapy (2-4 weeks) while waiting for SSRIs to take effect, due to addiction risk.
Surgical & Procedural Management
None.
Patient Counseling & Advice
Inform the patient that SSRIs take 4-6 weeks to reach full efficacy and may initially cause mild nausea or slightly increase anxiety in the first few days. Stress that therapy (CBT) is about learning tools to manage the worry, not necessarily eliminating all stress from life.
Follow-Up & Monitoring Schedule
Reassess every 2-4 weeks initially to monitor for medication side effects, specifically checking for emerging suicidal ideation (especially in young adults) or worsening anxiety. Once stable, assess every 3-6 months.
Preventive Strategies
Early intervention with therapy during adolescence if anxiety traits are prominent. Stress management training.
GAD is generally a chronic, lifelong condition with periods of exacerbation and remission. With optimal combination treatment (CBT + SSRI), up to 50-60% of patients achieve significant remission.